Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer.
Molecular and Clinical Characteristics of Patients with Non-Small Cell Lung Cancer Harboring KRAS G12V Mutations.
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial
Automated Detection of Focal Bone Marrow Lesions From MRI: A Multi-center Feasibility Study in Patients with Monoclonal Plasma Cell Disorders
Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Frontline Pembrolizumab or Methotrexate in Elderly, Frail, or Cisplatin-Ineligible Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of the Randomized Phase 2 Study ELDORANDO (AIO-KHT-0115)
Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer
Patient Characteristics and Different Decision Paths for Establishing Palliative Care for Patients Admitted via the Emergency Department.
Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti-EGFR-Based Maintenance for RAS wt Metastatic CRC-The PanaMa (AIO KRK0212) Trial.
Supplementary Figure S5 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Figure S3 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Figure S2 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S11 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Data from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S12 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S5 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S6 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S10 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S8 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S13 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S7 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S1 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S3 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S9 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Figure S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S2 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Figure S1 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.